Tumour-Induced Osteomalacia Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
In 2024, the global tumour-induced osteomalacia market recorded impressive revenue of US$ 135 Mn and the market is poised for further advancement, projecting to attain US$ 173 Mn by the year 2031.
What's Paving the Way for Tumour-Induced Osteomalacia Product Manufacturers?
""Vast Clinical Pipeline for Orphan Drug Development""
The field of medical research continually seeks to address unmet medical needs, and breakthroughs in cellular biology have illuminated pathways towards novel therapeutics. Small molecules like inhibitors are becoming pivotal in comprehending cellular microenvironments and signaling pathways. These molecules offer improved patient tolerability alongside treatment efficacy.
Notably, the tumour-induced osteomalacia treatment landscape boasts a limited clinical pipeline, with only one approved drug, Crystiva, manufactured by Ultragenix Pharmaceuticals and Kyowa Hakko Kirin Co., Ltd., along with its small molecule inhibitor Fibroblast growth factor 23 (FGF-23). This scarcity presents an opportune arena for pharmaceutical companies to invest in pioneering drug discoveries for underserved targets.
What Challenges Are Affecting Tumour-Induced Osteomalacia Demand?
""High-Cost of Treatment and Stringent Regulations""
The cost of treating tumour-induced osteomalacia can be substantial, hindering market expansion. Surgical procedures for tumour removal can cost between US$ 50,000 to US$ 100,000 in the U.S., with the annual expense for all treatments reaching billions.
Additionally, pricing sensitivity in emerging markets presents barriers to addressing rare diseases. Strict regulations governing cancer and immunological drugs on a global scale, including adherence to FDA and other standards, pose further challenges.
Regional Insights:
Why the U.S. Dominates the Tumour-Induced Osteomalacia Market?
Developed Healthcare Infrastructure & Fund Allocation for Rare Disease Therapeutics
The U.S. accounted for a significant market share in the global tumour-induced osteomalacia market in 2024. Its prominence can be attributed to a highly developed research infrastructure, strong collaborations between research institutes and hospitals, and dedicated programs and funds allocated for orphan drug development and rare disease research.
Japan: A Growing Market for Tumour-Induced Osteomalacia?
Growing Regulatory Approvals for Marketing in the Country
Japan is poised to exhibit growth in the global tumour-induced osteomalacia market with the emergence of new treatment modalities, post-marketing approvals, and the adoption of drugs approved by the FDA and EU. For instance, in August 2022, the European Commission granted Kyowa Kirin authorization to use CRYSVITA® (burosumab) as a therapy for tumor-induced osteomalacia.
India's Potential in the Tumour-Induced Osteomalacia Market
Large Patient Population and Huge Potential for New Market Entrants
India, with a notable market share in 2024, is projected to expand in the global tumour-induced osteomalacia market. Its burgeoning patient base and growing economy offer substantial opportunities for drug manufacturers, despite pricing competition. India presents lucrative prospects for manufacturing collaborations in the tumour-induced osteomalacia market space.
Competitive Landscape:
Leading pharmaceutical companies focus on partnerships to expand product portfolios. Emerging markets see continuous R&D investments, facilitating the development of new pharmaceuticals and drug combinations.
Key Companies Profiled:
• Ultragenyx Pharmaceutical Inc.
• Dishman Carbogen Amcis Ltd.
• Teva Pharmaceuticals
• Glenmark Pharmaceuticals
• Wockhardt Ltd
• FDC Limited
• Lupin Pharmaceuticals
• Zydus Cadila Healthcare Ltd.
• Intas Pharmaceuticals Ltd
• Macleods Pharmaceuticals
• G.C. Chemie Pharmie Ltd
• Santiago Life Sciences
Tumour-Induced Osteomalacia Industry Research Segmentation
Tumour-Induced Osteomalacia Market by Treatment:
• Drugs and Supplements
Burosumab -twza
Cinarcalcet
Calcium
Active Vitamin D (Calcitriol/α-calcitriol)
Phosphorus
• Surgery
Tumour-Induced Osteomalacia Market by Diagnosis:
• Laboratories
Elevated Blood Fibroblast Growth Factor 23 (FGF-23)
Serum Calcium, PTH, Vitamin D
Hyperphosphaturia (Secondary Effects of FDF-23)
Hypophosphatemia (Secondary Effects of FDF-23)
• Bone Scan
Magnetic Resonance Imaging (MRI)
Computed Tomography (CT Scans)
• Differential Diagnosis
Vitamin D Metabolism and Deficiency
Osteoporosis
Renal Osteodystrophy
Others
Tumour-Induced Osteomalacia Market by End User:
• Hospitals
• Specialty Clinics
• Others
Tumour-Induced Osteomalacia Market by Country:
• U.S.
• Canada
• Japan
• European Countries
• China
• Mexico
• South Korea
• India
• Brazil
• Australia
Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.